{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Stock Hits 52-Week Low at Rs.140.1 Amidst Continued Downtrend
Nath Bio-Genes (India) has reached a new 52-week low of Rs.140.1, marking a significant decline amid a sustained downward trend over recent sessions. The stock’s performance contrasts sharply with broader market gains, reflecting ongoing pressures within the company’s financial and operational metrics.
Nath Bio-Genes Sees Revision in Market Assessment Amidst Challenging Fundamentals
Nath Bio-Genes has experienced a revision in its market evaluation, reflecting shifts in its fundamental and technical outlook. The company’s recent performance metrics and investor participation trends have contributed to this updated assessment, signalling caution for stakeholders in the Other Agricultural Products sector.
Why is Nath Bio-Genes falling/rising?
On 24-Nov, Nath Bio-Genes (India) Ltd witnessed a significant decline in its share price, falling by 5.42% to close at ₹150.00. This drop reflects broader challenges faced by the stock over recent weeks and months, as well as sector-wide pressures and diminishing investor engagement.
Why is Nath Bio-Genes falling/rising?
As of 19-Nov, Nath Bio-Genes (India) Ltd's stock price is Rs 160.65, down 1.83%, and has declined 3.72% over the last three days. It is underperforming against the Sensex and trading below all major moving averages, despite a slight increase in investor participation.
Nath Bio-Genes Q2 FY26: Seasonal Slump Masks Underlying Growth as Stock Struggles
Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹320.00 crores, reported a consolidated net profit of ₹2.75 crores for Q2 FY26 (Jul-Sep'25), representing a sharp 92.62% quarter-on-quarter decline but a robust 147.75% year-on-year improvement. The dramatic sequential fall reflects the company's highly seasonal business model, where the first quarter typically captures the bulk of annual revenues during the peak agricultural season.
How has been the historical performance of Nath Bio-Genes?
Nath Bio-Genes has shown consistent growth in net sales and profitability over the past four years, with net sales increasing from 278.36 crore in March 2022 to 364.91 crore in March 2025, and profit before tax improving from a loss of 63.43 crore to a profit of 40.04 crore in the same period. The company has demonstrated resilience, with positive earnings per share rising from -35.46 to 20.32.
How has been the historical performance of Nath Bio-Genes?
Nath Bio-Genes has demonstrated consistent growth in net sales and profitability over the past four years, with net sales reaching 364.91 Cr in March 2025 and profit after tax increasing to 38.06 Cr. Despite a slight decline in earnings per share, the company has shown a positive cash flow and overall recovery in financial performance.
Nath Bio-Genes Faces Shift to Bearish Outlook Amid Declining Investor Confidence
Nath Bio-Genes (India) has undergone a recent evaluation adjustment, reflecting a shift in its technical outlook. The company has reported a -10.61% return over the past year and a decline in institutional investor participation. Additionally, it has experienced a -0.69% CAGR growth in operating profits over five years.
When is the next results date for Nath Bio-Genes?
The next results date for Nath Bio-Genes is 13 November 2025.
Nath Bio-Genes Faces Profitability Challenges Amid Shift in Market Sentiment
Nath Bio-Genes (India) has recently experienced a change in its evaluation, with its technical trend shifting to mildly bearish. The company reported flat financial performance for the quarter ending June 2025, and its five-year operating profit CAGR stands at -0.69%. Institutional investor participation has declined, reflecting cautious sentiment.
How has been the historical performance of Nath Bio-Genes?
Nath Bio-Genes has shown consistent growth in net sales and profitability over the past four years, with net sales increasing from INR 278.36 crore in March 2022 to INR 364.91 crore in March 2025, and profit after tax rising from a loss of INR 67.39 crore to a profit of INR 38.06 crore in the same period. The earnings per share improved significantly from a negative INR 35.46 to INR 20.32.
Nath Bio-Genes Faces Bearish Outlook Amid Declining Returns and Investor Participation
Nath Bio-Genes (India) has recently experienced a score revision reflecting a bearish outlook. The company's performance shows a -9.05% return over the past year, contrasting with the Sensex's 5.78% gain. Long-term growth metrics indicate challenges, while the stock trades at a discount relative to peers.
How has been the historical performance of Nath Bio-Genes?
Nath Bio-Genes has shown consistent growth, with net sales increasing from 278.36 Cr in Mar'22 to 364.91 Cr in Mar'25, and turning losses into profits, with profit after tax rising from a loss of 67.39 Cr to a profit of 38.06 Cr during the same period. The earnings per share improved significantly from -35.46 to 20.32.
Nath Bio-Genes Faces Declining Investor Confidence Amidst Flat Financial Performance
Nath Bio-Genes (India) has recently adjusted its evaluation score, reflecting a change in technical trends. The company reported flat performance for Q1 FY25-26 and has faced challenges with a negative CAGR in operating profits over five years. Institutional investor participation has declined, indicating cautious sentiment.
How has been the historical performance of Nath Bio-Genes?
Nath Bio-Genes has shown consistent growth in net sales and profits over the past four years, with net sales reaching 364.91 Cr and profit after tax at 38.06 Cr in March 2025. Despite a slight decrease in earnings per share to 20.32, the company maintained strong cash flow and a healthy financial trajectory.
Nath Bio-Genes Faces Evaluation Shift Amid Declining Institutional Interest and Profitability Challenges
Nath Bio-Genes (India) has recently experienced a revision in its evaluation due to changes in technical trends. The company has faced challenges, including a decline in institutional investor participation and underperformance compared to the BSE500 index, while trading at a discount relative to its peers.
How has been the historical performance of Nath Bio-Genes?
Nath Bio-Genes has shown consistent growth in net sales and profitability over the past four years, with net sales increasing from 278.36 Cr in Mar'22 to 364.91 Cr in Mar'25, and profit after tax improving from a loss of 67.39 Cr to a profit of 38.06 Cr in the same period. Despite a decrease in cash flow from operating activities, the company maintains a healthy cash position with closing cash equivalents rising to 88.00 Cr.
Nath Bio-Genes Faces Mixed Performance Amid Shift in Evaluation Score
Nath Bio-Genes (India) has recently seen a change in its evaluation score, indicating a shift in technical trends. The company's recent stock performance has been mixed, with a short-term gain but a year-to-date decline. Financial metrics show flat operating profits and reduced institutional investor participation, reflecting cautious sentiment.
How has been the historical performance of Nath Bio-Genes?
Nath Bio-Genes has shown consistent growth over the past four years, with net sales increasing from 278.36 Cr in Mar'22 to 364.91 Cr in Mar'25, and a turnaround in profitability from losses to profits in both pre-tax and after-tax earnings. The company's EPS improved from -35.46 to 20.32, indicating a strong recovery and enhanced operational efficiency.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
